SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-007579
Filing Date
2024-02-28
Accepted
2024-02-28 16:07:21
Documents
16
Period of Report
2024-02-28
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lyel-20240228.htm   iXBRL 8-K 27178
2 EX-99.1 lyel-20240228x8kexx991.htm EX-99.1 123674
6 a0000.jpg GRAPHIC 6782
  Complete submission text file 0001628280-24-007579.txt   299261

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lyel-20240228.xsd EX-101.SCH 1895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lyel-20240228_lab.xml EX-101.LAB 23834
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lyel-20240228_pre.xml EX-101.PRE 12504
17 EXTRACTED XBRL INSTANCE DOCUMENT lyel-20240228_htm.xml XML 2725
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

IRS No.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 24695285
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)